AcelRx Pharmaceuticals Overview
- Founded
- 2005
- Status
- Public
- Employees
- 54
- Stock Symbol
- ACRX
- Investments
- 1
- Share Price
- $0.48
- (As of Tuesday Closing)
AcelRx Pharmaceuticals General Information
Description
AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its product portfolio includes DSUVIA and Zalviso for Moderate-to-severe acute pain. The company's products under pipeline are ARX-02 and ARX-03. The majority of its revenue is generated from DSUVIA product sales in the United States.
Contact Information
Website
www.acelrx.com
Formerly Known As
Surx
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Therapeutic Devices
Stock Exchange
NAS
Primary Office
- 351 Galveston Drive
- Redwood City, CA 94063
- United States
+1 (650) 000-0000
AcelRx Pharmaceuticals Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.48 | $0.47 | $0.43 - $2.94 | $60.3M | 128M | 1.17M | -$0.33 |
AcelRx Pharmaceuticals Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 |
|---|---|---|---|---|
| EV | 88,994 | 107,153 | 116,340 | 127,052 |
| Revenue | 3,554 | 5,416 | 2,289 | 2,151 |
| EBITDA | (35,140) | (39,110) | (52,537) | (35,152) |
| Net Income | (36,100) | (40,379) | (53,240) | (47,149) |
| Total Assets | 72,263 | 66,295 | 91,356 | 120,533 |
| Total Debt | 20,396 | 25,599 | 29,757 | 11,991 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
AcelRx Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore AcelRx Pharmaceuticals‘s full profile, request access.
Request a free trialAcelRx Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is available in the PitchBook Platform. To explore AcelRx Pharmaceuticals‘s full profile, request access.
Request a free trialAcelRx Pharmaceuticals Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of the
Pharmaceuticals
Redwood City, CA
54
As of 2020
00000
000000 - 000
00000
000000 0
ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in v
00000000000 0000000
Ardsley, NY
000
As of 0000
00000
0.00
0000-00-00
000000&0
00000 00
ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse c
000000000000000
Solana Beach, CA
0
As of 0000
0000
000000 - 000
0000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialAcelRx Pharmaceuticals Competitors (11)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Acorda Therapeutics | Formerly VC-backed | Ardsley, NY | 000 | 00000 | 000000&0 | |
| 00000 000000 | Formerly VC-backed | Solana Beach, CA | 0 | 0000 | 000000 - 000 | 0000 |
| 00000 000000000000 | Formerly VC-backed | Bridgewater, NJ | 0000 | 00000 | 000000&0 | |
| 00000000 000000000 | Corporation | Henderson, NV | 000 | 00000 | 000000 - 000 | 00000 |
| 0000 000000000000 | Formerly VC-backed | Bridgewater, NJ | 000 | 00000 | 00000000000 | 00000 |
AcelRx Pharmaceuticals Patents
AcelRx Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| ES-2784486-T3 | Apparatus and methods for dispensing oral transmucosal dosage forms | Active | 30-Oct-2015 | 0000000000 | |
| EP-3682915-A1 | Apparatus and methods for dispensing oral transmucosal dosage forms | Pending | 30-Oct-2015 | 0000000000 | 0 |
| EP-3368097-A1 | Apparatus and methods for dispensing oral transmucosal dosage forms | Granted | 30-Oct-2015 | 0000000000 | |
| EP-3368097-B1 | Apparatus and methods for dispensing oral transmucosal dosage forms | Active | 30-Oct-2015 | 0000000000 | |
| EP-3368097-A4 | Apparatus and methods for dispensing oral transmucosal dosage forms | Granted | 30-Oct-2015 | A61J7/0076 | 0 |
AcelRx Pharmaceuticals Executive Team (18)
AcelRx Pharmaceuticals Board Members (12)
| Name | Representing | Role | Since |
|---|---|---|---|
| Adrian Adams | Self | Chairman & Board Member | 000 0000 |
| Howard Rosen | AcelRx Pharmaceuticals | Board Member | 000 0000 |
| Jill Broadfoot | Self | Board Member | 000 0000 |
| Mark Edwards | Self | Board Member | 000 0000 |
| Mark Wan | Three Arch Partners | Board Member | 000 0000 |
AcelRx Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialAcelRx Pharmaceuticals Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 000000 | 10-Jan-2022 | 0000000000 | 000.00 | Pharmaceuticals |